Table 1.
Patient characteristics in three quantiled TMB groups (N = 273 patients)
| TMB (0–1 mutations/mb) N = 39 |
TMB (2–11 mutations/mb) N = 174 |
TMB (≥ 12 mutations/mb) N = 60 |
p value | |
|---|---|---|---|---|
| TMB (Mean ± SD) | 0 | 5.2 ± 2.5 | 37.4 ± 47.6 | Not applicable |
| Median | 0 | 5 | 20 | |
| SUVmax (Mean ± SD) | 4.5 ± 3.9 | 8.4 ± 7.8 | 11.2 ± 8.5 | p < 0.0001 |
| Median (range) | 3.9 (0–16.4) | 6.8 (0–74.0) | 9.2 (1.6–49.6) | |
| Age at time of biopsy (years) (Mean ± SD) | 68.5 ± 12.5 | 63.9 ± 13.7 | 68.3 ± 12.8 | p = 0.03 |
| Median (range) | 71 (34–91) | 65 (23–96) | 70 (28–89) | |
| Women (N (%)) | 22 (14%) | 104 (67%) | 30 (19%) | p = 0.4 |
| Men (N (%)) | 17 (14%) | 70 (60%) | 30 (26%) | |
| Melanoma (N = 15) | 2 (13%) | 4 (27%) | 9 (60%) | p < 0.001 |
| Lung cancer (N = 61) | 5 (8%) | 38 (62%) | 18 (30%) | |
| Gastrointestinal (N = 36) | 3 (9%) | 29 (80%) | 4 (11%) | |
| Breast (N = 43) | 7 (16%) | 33 (77%) | 3 (7%) | |
| Other (N = 118)* | 22 (19%) | 70 (59%) | 26 (22%) |
SD standard deviation, SUV standardized uptake value, TMB tumor mutational burden
*Other cancers consisted of head and neck, adrenal, bladder, ovary, uterus, prostate, musculoskeletal, and hematologic malignancies, and cancers of unknown primary